Skip to main content

Table 1 Demographic, clinical, and laboratory characteristics of SLE patients with proliferative nephritis

From: Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis

  Patients (n= 58)
  n(% or range)
Sex: F/M 54/4 (93/7)
Mean age (years)    39 ± 12 (22-75)
Mean age at SLE diagnosis (years)    26 ± 11 (8-66)
Mean age at nephritis (years)    29 ± 12 (8-73)
Mean duration of follow-up (months)    97 (1-273)
Cardiovascular risk factors    35 (58)
Positive aPL    31 (53.4)
APS    8 (14.8)
ANA (+)    58 (100)
a-DNA (+)    49 (84.5)
a-Ro (+)    21 (42.9)
a-Sm (+)    16 (33.3)
a-RNP (+)    11 (22.9)
Low complement levels    52 (91.2)
Treatment before first renal biopsy  
   Antiaggregation    20/65 (31)
   Oral anticoagulation    2/65 (3.1)
   Glucocorticoids    50/65 (77)
≤7.5 mg/d prednisone    42%
< 7.5 to 30 mg/d prednisone    43%
> 30 to 60 mg/d prednisone    10%
> 1 mg/kg/d prednisone    5%
   Azathioprine    13/65 (20)
   Antimalarials    20/65 (31)
ISN/RPS nephritis classification:  
   Type II    2/65 (3)
   Type III-A    13/65 (20)
   Type III-A/C    4/65 (6.1)
   Type III-A + V    2/65 (3)
   Type IV-SA    10/65 (15.4)
   Type IV-SA/C    4/65 (6.1)
   Type IV-GA    23/65 (35.4)
   Type IV-GA/C    5/65 (7.7)
   Type IV-GA/C + V    2/65 (3)
24 hours proteinuria (mg)a    3,355.1 ± 3,372.3 (230-19,700)
Hematuria (+)a    56 (86.2)
Leukocyturia (+)a    52 (80)
Cellular casts (+)a    42 (64.6)
Mean serum creatinine (mg/dl)a    1.1 ± 0.5 (0.4-3.4)
Mean creatinine clearance (ml/min)a    91.8 ± 44.4 (25-289)
Renal failurea    17 (26.2)
HBPa    35 (53.8)
SLEDAIa    20.4 (4-36)
Response to treatment    50 (83.3)
Mean time of response (months)    15 ± 19 (1-101)
  1. Cardiovascular risk factors include high blood pressure (HBP), diabetes, hypercholesterolemia and/or hypertriglyceridemia, smoking, and hormonal contraception. aValues at renal biopsy.